Solution conformations of the substrates and inhibitor of hepatitis C virus NS3 protease

被引:0
|
作者
Lee, JH
Bang, K
Jung, JW
Ahn, IA
Ro, S
Lee, W
机构
[1] Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120740, South Korea
[2] LG Chem, Biotech Res Inst, Taejon 305380, South Korea
关键词
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Hepatitis C virus (HCV) has been known to be an enveloped virus with a positive strand RNA genome and the major agent of the vast majority of transfusion associated cases of hepatitis. For viral replication, HCV structural proteins are first processed by host cell signal peptidases and NS2/NS3 site of the nonstructural protein is cleaved by a zinc-dependent protease NS2 with N-terminal NS3. The four remaining junctions are cleaved by a separate NS3 protease. The solution conformations of NS4B/5A, NS5A/5B substrates and NS5A/5B inhibitor have been determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy. NMR data suggested that the both NS5A/5B substrate and inhibitor appeared to have a folded turn-like conformation not only between P1 and P6 position but also C-terminal region, whereas the NS4B/5A substrate exhibited mostly extended conformation. In addition, we have found that the conformation of the NS5A/5B inhibitor slightly differs from that of NS5A/5B substrate peptide, suggesting different binding mode for NS3 protease. These findings will be of importance for designing efficient inhibitor to suppress HCV processing.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 50 条
  • [1] Activity of purified hepatitis C virus protease NS3 on peptide substrates
    Steinkuhler, C
    Urbani, A
    Tomei, L
    Biasiol, G
    Sardana, M
    Bianchi, E
    Pessi, A
    DeFrancesco, R
    JOURNAL OF VIROLOGY, 1996, 70 (10) : 6694 - 6700
  • [2] Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
    McPhee, Fiona
    Friborg, Jacques
    Levine, Steven
    Chen, Chaoqun
    Falk, Paul
    Yu, Fei
    Hernandez, Dennis
    Lee, Min S.
    Chaniewski, Susan
    Sheaffer, Amy K.
    Pasquinelli, Claudio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3670 - 3681
  • [3] An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    Lamarre, D
    Anderson, PC
    Bailey, M
    Beaulieu, P
    Bolger, G
    Bonneau, P
    Bös, M
    Cameron, DR
    Cartier, M
    Cordingley, MG
    Faucher, AM
    Goudreau, N
    Kawai, SH
    Kukolj, G
    Lagacé, L
    LaPlante, SR
    Narjes, H
    Poupart, MA
    Rancourt, J
    Sentjens, RE
    St George, R
    Simoneau, B
    Steinmann, G
    Thibeault, D
    Tsantrizos, YS
    Weldon, SM
    Yong, CL
    Llinàs-Brunet, M
    NATURE, 2003, 426 (6963) : 186 - 189
  • [4] An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    Daniel Lamarre
    Paul C. Anderson
    Murray Bailey
    Pierre Beaulieu
    Gordon Bolger
    Pierre Bonneau
    Michael Bös
    Dale R. Cameron
    Mireille Cartier
    Michael G. Cordingley
    Anne-Marie Faucher
    Nathalie Goudreau
    Stephen H. Kawai
    George Kukolj
    Lisette Lagacé
    Steven R. LaPlante
    Hans Narjes
    Marc-André Poupart
    Jean Rancourt
    Roel E. Sentjens
    Roger St George
    Bruno Simoneau
    Gerhard Steinmann
    Diane Thibeault
    Youla S. Tsantrizos
    Steven M. Weldon
    Chan-Loi Yong
    Montse Llinàs-Brunet
    Nature, 2003, 426 : 186 - 189
  • [5] Hepatitis C virus NS3 serine protease interacts with the serpin Cl inhibitor
    Drouet, C
    Bouillet, L
    Csopaki, F
    Colomb, MG
    FEBS LETTERS, 1999, 458 (03) : 415 - 418
  • [6] Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor
    Heintges, T
    Encke, J
    Putlitz, JZ
    Wands, JR
    JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) : 671 - 680
  • [7] ASUNAPREVIR HCV Serine Protease NS3 Inhibitor Treatment of Hepatitis C Virus
    Reviriego, C.
    DRUGS OF THE FUTURE, 2012, 37 (04) : 247 - 254
  • [8] Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
    de Bruijne, J.
    Thomas, X. V.
    Rebers, S. P.
    Weegink, C. J.
    Treitel, M. A.
    Hughes, E.
    Bergmann, J. F.
    de Knegt, R. J.
    Janssen, H. L. A.
    Reesink, H. W.
    Molenkamp, R.
    Schinkel, J.
    JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) : 779 - 789
  • [9] Hepatitis C virus NS3/4A protease
    Kwong, AD
    Kim, JL
    Rao, G
    Lipovsek, D
    Raybuck, SA
    ANTIVIRAL RESEARCH, 1998, 40 (1-2) : 1 - 18
  • [10] Hepatitis C virus NS3/4A protease
    Kwong, AD
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (06) : 485 - 490